Biovica International AB (publ) (BIOVIC-B) - Total Liabilities

Latest as of July 2025: Skr31.14 Million SEK ≈ $3.35 Million USD

Based on the latest financial reports, Biovica International AB (publ) (BIOVIC-B) has total liabilities worth Skr31.14 Million SEK (≈ $3.35 Million USD) as of July 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BIOVIC-B operating cash flow to assess how effectively this company generates cash.

Biovica International AB (publ) - Total Liabilities Trend (2014–2025)

This chart illustrates how Biovica International AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check Biovica International AB (publ) asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Biovica International AB (publ) Competitors by Total Liabilities

The table below lists competitors of Biovica International AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
Tokyo Plast International Limited
NSE:TOKYOPLAST
India Rs648.59 Million
Phoenix New Media Limited
NYSE:FENG
USA $541.82 Million
Neola Medical AB
ST:NEOLA
Sweden Skr4.15 Million
STO Co. Ltd
KQ:098660
Korea ₩54.54 Billion
GEN Restaurant Group, Inc. Class A Common Stock
NASDAQ:GENK
USA $231.85 Million
Huachen AI Parking Management Technology Holding Co Ltd
NASDAQ:HCAI
USA $21.65 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Biovica International AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIOVIC-B market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.86 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.56 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.21 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.55 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Biovica International AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Biovica International AB (publ) (2014–2025)

The table below shows the annual total liabilities of Biovica International AB (publ) from 2014 to 2025.

Year Total Liabilities Change
2025-04-30 Skr21.74 Million
≈ $2.34 Million
-37.46%
2024-04-30 Skr34.77 Million
≈ $3.74 Million
+3.32%
2023-04-30 Skr33.65 Million
≈ $3.62 Million
+22.18%
2022-04-30 Skr27.54 Million
≈ $2.96 Million
+175.73%
2021-04-30 Skr9.99 Million
≈ $1.07 Million
-17.05%
2020-04-30 Skr12.04 Million
≈ $1.30 Million
+37.43%
2019-04-30 Skr8.76 Million
≈ $942.93K
+24.14%
2018-04-30 Skr7.06 Million
≈ $759.55K
+25.19%
2017-04-30 Skr5.64 Million
≈ $606.74K
+73.26%
2016-04-30 Skr3.25 Million
≈ $350.18K
-65.54%
2015-04-30 Skr9.44 Million
≈ $1.02 Million
+134.67%
2014-04-30 Skr4.02 Million
≈ $433.09K
--

About Biovica International AB (publ)

ST:BIOVIC-B Sweden Biotechnology
Market Cap
$9.39 Million
Skr87.27 Million SEK
Market Cap Rank
#27024 Global
#590 in Sweden
Share Price
Skr0.32
Change (1 day)
-9.43%
52-Week Range
Skr0.28 - Skr1.02
All Time High
Skr66.10
About

Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more